MicroRNA-3162-5p-Mediated Crosstalk Between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer
Overview
Authors
Affiliations
Background: MicroRNAs mediate biological processes through preferential binding to the 3' untranslated region (3' UTR) of target genes. Studies have shown their association with prostate cancer (PCa) risk through single-nucleotide polymorphisms (SNPs), known as miRSNPs. In a European cohort, 22 PCa risk-associated miRSNPs have been identified. The most significant miRSNP in the 3' UTR of () created a binding site for miR-3162-5p. Here we investigated the miR-3162-5p-KLK interaction and the clinical implication of miR-3162-5p in PCa.
Methods: We tested the role of miR-3162-5p in PCa etiology using IncuCyte live-cell imaging and anchorage-independent growth assays. The effect of miR-3162-5p on KLK and androgen receptor (AR) expression was measured by RT-quantitative (q)PCR and target pulldown assays. KLK3 proteolytic activity was determined by DELFIA immunoassay. Mass spectrometry identified pathways affected by miR-3162-5p. miR-3162-5p expression was measured in clinical samples using RT-qPCR.
Results: miR-3162-5p affected proliferation, migration, and colony formation of LNCaP cells by regulating the expression of KLK2-4 and AR by direct targeting. KLK3 protein expression was regulated by miR-3162-5p consistent with lower KLK3 proteolytic activity observed in LNCaP-conditioned media. KLK/AR pulldown and mass spectrometry analysis showed a potential role of miR-3162-5p in metabolic pathways via KLK/AR and additional targets. Increased miR-3162-5p expression was observed in prostate tumor tissues with higher Gleason grade.
Conclusions: Our study provides an insight into possible involvement of miR-3162-5p in PCa etiology by targeting KLKs and AR. It highlights clinical utility of miR-3162-5p and its interactive axis as a new class of biomarkers and therapeutic targets for PCa.
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.
Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P Nat Commun. 2024; 15(1):9587.
PMID: 39505858 PMC: 11541583. DOI: 10.1038/s41467-024-52472-6.
Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.
Davoudi F, Moradi A, Becker T, Lock J, Abbey B, Fontanarosa D Curr Treat Options Oncol. 2023; 24(10):1451-1471.
PMID: 37561382 PMC: 10547634. DOI: 10.1007/s11864-023-01121-z.
Sams K, Mukai C, Marks B, Mittal C, Demeter E, Nelissen S Reprod Biol Endocrinol. 2022; 20(1):150.
PMID: 36224627 PMC: 9555066. DOI: 10.1186/s12958-022-01018-w.
The Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases.
Bielska A, Skwarska A, Kretowski A, Niemira M Int J Mol Sci. 2022; 23(3).
PMID: 35163477 PMC: 8835816. DOI: 10.3390/ijms23031553.
Remodelling of the tumour microenvironment by the kallikrein-related peptidases.
Srinivasan S, Kryza T, Batra J, Clements J Nat Rev Cancer. 2022; 22(4):223-238.
PMID: 35102281 DOI: 10.1038/s41568-021-00436-z.